AngioDynamics

History

Year	Detail
1988	AngioDynamics, initially known as E-Z-EM, was established by founders Eamonn P. Hobbs and Howard S. Stern.
1990	AngioDynamics launched several Angiographic Catheter products, including Soft-Vu, OmniFlush, AngiOptic, and the Abscession General Drainage Catheter.
2004	AngioDynamics became a public company listed on the Nasdaq and Nasdaq Health Care Index to improve patient care.
	AngioDynamics acquired RITA Medical Systems, which added thermal ablation technologies that enabled AngioDynamics to enter the oncology treatment space.
2009	AngioDynamics acquired Oncobionic, an Irreversible Electroporation (IRE) technology provider, which brought the noteworthy NanoKnife system.
2019	The FDA approved AngioDynamics’ DIRECT Study on the usage of the system for the treatment of Stage III pancreatic cancer.
2020	AngioDynamics commercially launched the Auryon Atherectomy System, an advanced technology for treating Peripheral Artery Disease in the U.S.
2021	AngioDynamics received FDA approval for the Pivotal Study of the NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population (PRESERVE).
2023	Since 2012, AngioDynamics has partnered with Cardiva, a Spanish-based medical device company, to develop an existing collaboration and distribute AngioDynamics’ vascular access portfolio in Spain and Portugal.